Free Trial
Thank you for registering! Take a moment to confirm your subscription to MarketBeat Daily Ratings so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
NYSE:ALC

Alcon (ALC) Stock Price, News & Analysis

$89.08
-0.63 (-0.70%)
(As of 06/28/2024 ET)
Today's Range
$88.75
$89.41
50-Day Range
$77.57
$92.26
52-Week Range
$69.44
$92.65
Volume
686,097 shs
Average Volume
711,353 shs
Market Capitalization
$43.93 billion
P/E Ratio
42.22
Dividend Yield
N/A
Price Target
$94.71

Alcon MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
6.3% Upside
$94.71 Price Target
Short Interest
Bearish
0.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.33mentions of Alcon in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
14.43%
From $3.05 to $3.49 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.53 out of 5 stars

Medical Sector

696th out of 915 stocks

Ophthalmic Goods Industry

7th out of 8 stocks

ALC stock logo

About Alcon Stock (NYSE:ALC)

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

ALC Stock Price History

ALC Stock News Headlines

Who are Nvidia’s Silent Partners?
Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.
Who are Nvidia’s Silent Partners?
Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.
Here's what to expect from Alcon's earnings
See More Headlines

Company Calendar

Last Earnings
5/13/2024
Ex-Dividend for 5/16 Dividend
5/14/2024
Dividend Payable
5/16/2024
Today
6/29/2024
Next Earnings (Estimated)
8/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
Health Care Facilities
CUSIP
04544X30
Employees
25,000
Year Founded
1945

Price Target and Rating

Average Stock Price Target
$94.71
High Stock Price Target
$105.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+6.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
15 Analysts

Profitability

Net Income
$974 million
Pretax Margin
9.98%

Debt

Sales & Book Value

Annual Sales
$9.46 billion
Cash Flow
$5.21 per share
Book Value
$41.83 per share

Miscellaneous

Free Float
485,605,000
Market Cap
$43.93 billion
Optionable
Optionable
Beta
0.97

Social Links

Key Executives

  • Mr. F. Michael Ball (Age 69)
    Executive Chairman
    Comp: $1.17M
  • Mr. Arthur B. Cummings M.D. (Age 62)
    Executive Director
    Comp: $284.68k
  • Mr. David J. Endicott (Age 59)
    CEO & Director
    Comp: $4.82M
  • Mr. Timothy C. Stonesifer (Age 57)
    Chief Financial Officer
  • Margaret Buckley
    Chief Accounting Officer
  • Dr. Franck Leveiller
    Senior VP, Head of Global R&D and Chief Scientific Officer
  • Ms. Sue-Jean Lin (Age 65)
    Senior VP and Chief Information & Transformation Officer
  • Mr. Royce R. Bedward (Age 58)
    Senior VP, General Counsel & Corporate Secretary
  • Ms. Kimberly Martin (Age 49)
    Senior VP, Chief HR Officer & Corporate Communications
  • Mr. Laurent Attias (Age 56)
    Head of Corporate Development, Strategy, BD&L and M&A

Should I Buy Alcon Stock? ALC Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Alcon Inc.:

  • Alcon Inc. stock price has been steadily increasing over the past year, showing positive momentum.
  • Alcon Inc. has a strong market position in the ophthalmic pharmaceuticals and eye care products industry, providing stability and growth potential.
  • Recent product innovations, such as the launch of the latest eye surgery equipment, have positioned Alcon Inc. as a leader in cutting-edge technology.
  • Alcon Inc. has a history of consistent dividend payments, offering investors a source of passive income.
  • Positive analyst sentiment towards Alcon Inc., with an average rating of "Buy" and a price target above the current market price.

Cons

Investors should be bearish about investing in Alcon Inc. for these reasons:

  • Alcon Inc. faces intense competition in the ophthalmic industry, which could impact its market share and profitability.
  • Fluctuations in foreign exchange rates may affect Alcon Inc.'s international operations and financial performance.
  • Regulatory changes in the healthcare sector could lead to increased compliance costs for Alcon Inc., impacting its bottom line.
  • Economic downturns or recessions could reduce consumer spending on elective eye care procedures, affecting Alcon Inc.'s revenue streams.
  • Alcon Inc. may face challenges in maintaining consistent growth due to market saturation and evolving consumer preferences.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, June 8, 2024. Please send any questions or comments about these Alcon pros and cons to contact@marketbeat.com.

ALC Stock Analysis - Frequently Asked Questions

Should I buy or sell Alcon stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alcon in the last year. There are currently 2 sell ratings, 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALC shares.
View ALC analyst ratings
or view top-rated stocks.

What is Alcon's stock price target for 2024?

15 brokerages have issued 1 year price objectives for Alcon's shares. Their ALC share price targets range from $65.00 to $105.00. On average, they anticipate the company's share price to reach $94.71 in the next twelve months. This suggests a possible upside of 6.3% from the stock's current price.
View analysts price targets for ALC
or view top-rated stocks among Wall Street analysts.

How have ALC shares performed in 2024?

Alcon's stock was trading at $78.12 on January 1st, 2024. Since then, ALC shares have increased by 14.0% and is now trading at $89.08.
View the best growth stocks for 2024 here
.

Are investors shorting Alcon?

Alcon saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 3,980,000 shares, an increase of 22.1% from the April 30th total of 3,260,000 shares. Based on an average daily volume of 924,900 shares, the short-interest ratio is currently 4.3 days. Approximately 0.8% of the company's stock are sold short.
View Alcon's Short Interest
.

When is Alcon's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 20th 2024.
View our ALC earnings forecast
.

How were Alcon's earnings last quarter?

Alcon Inc. (NYSE:ALC) issued its quarterly earnings data on Monday, May, 13th. The healthcare company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.06. The healthcare company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.46 billion. Alcon had a trailing twelve-month return on equity of 6.87% and a net margin of 10.96%.

How often does Alcon pay dividends? What is the dividend yield for Alcon?

Alcon declared an annual dividend on Friday, May 10th. Investors of record on Wednesday, May 15th will be given a dividend of $0.156 per share on Thursday, May 16th. This represents a yield of 0.21%. The ex-dividend date is Tuesday, May 14th. This is an increase from the stock's previous annual dividend of $0.13.
Read our dividend analysis for ALC
.

What guidance has Alcon issued on next quarter's earnings?

Alcon updated its FY24 earnings guidance on Tuesday, May, 14th. The company provided earnings per share guidance of $3.00-3.10 for the period, compared to the consensus estimate of $3.04. The company issued revenue guidance of $9.9-10.1 billion, compared to the consensus revenue estimate of $9.98 billion.

What is Greg D. Wight's approval rating as Alcon's CEO?

6 employees have rated Alcon Chief Executive Officer Greg D. Wight on Glassdoor.com. Greg D. Wight has an approval rating of 100% among the company's employees. This puts Greg D. Wight in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alcon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alcon investors own include AT&T (T), Novartis (NVS), Verizon Communications (VZ), International Business Machines (IBM), Intel (INTC), Pfizer (PFE), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Exxon Mobil (XOM) and AbbVie (ABBV).

Who are Alcon's major shareholders?

Alcon's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.80%), Clearbridge Investments LLC (1.92%), Zurcher Kantonalbank Zurich Cantonalbank (1.66%), Bank of New York Mellon Corp (1.15%), Sustainable Growth Advisers LP (0.80%) and AMF Tjanstepension AB (0.70%).

How do I buy shares of Alcon?

Shares of ALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Alcon have any subsidiaries?
The following companies are subsidiares of Alcon: Alcon (China) Ophthalmic Product Co. Ltd., Alcon Finance Corporation, Alcon Japan Ltd., Alcon Laboratories Inc., Alcon Pharmaceuticals Ltd., Alcon Research LLC, and Alcon Vision LLC.
Read More
This page (NYSE:ALC) was last updated on 6/30/2024 by MarketBeat.com Staff

From Our Partners